CNS Lupus Questions & Answers

1. Honczarenko K, Budzianowska A, Ostanek L. Neurological syndromes in systemic lupus erythematosus and their association with antiphospholipid syndrome. Neurol Neurochir Pol. 2008 Nov-Dec. 42(6):513-7. [QxMD MEDLINE Link].

2. Hawro T, Bogucki A, Sysa-Jedrzejowska A, Bogaczewicz J, Wozniacka A. [Neurological disorders in systemic lupus erythematosus patients]. Pol Merkur Lekarski. 2009 Jan. 26(151):43-8. [QxMD MEDLINE Link].

3. Greenberg BM. The neurologic manifestations of systemic lupus erythematosus. Neurologist. 2009 May. 15(3):115-21. [QxMD MEDLINE Link].

4. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999 Apr. 42(4):599-608. [QxMD MEDLINE Link].

5. Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2010 Mar. 69(3):529-35. [QxMD MEDLINE Link]. [Full Text].

6. Steup-Beekman GM, Zirkzee EJ, Cohen D, Gahrmann BM, Emmer BJ, Steens SC. Neuropsychiatric manifestations in patients with systemic lupus erythematosus: epidemiology and radiology pointing to an immune-mediated cause. Ann Rheum Dis. 2013 Apr. 72 Suppl 2:ii76-9. [QxMD MEDLINE Link].

7. Borowoy AM, Pope JE, Silverman E, Fortin PR, Pineau C, Smith CD. Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort. Semin Arthritis Rheum. 2012 Oct. 42(2):179-85. [QxMD MEDLINE Link].

8. Unterman A, Nolte JE, Boaz M, Abady M, Shoenfeld Y, Zandman-Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011 Aug. 41(1):1-11. [QxMD MEDLINE Link].

9. Mina R, Brunner HI. Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?. Rheum Dis Clin North Am. 2010 Feb. 36(1):53-80, vii-viii. [QxMD MEDLINE Link]. [Full Text].

10. Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol. 2010 Sep. 6(9):538-46. [QxMD MEDLINE Link].

11. Kampylafka EI, Alexopoulos H, Kosmidis ML, Panagiotakos DB, Vlachoyiannopoulos PG, Dalakas MC. Incidence and prevalence of major central nervous system involvement in systemic lupus erythematosus: a 3-year prospective study of 370 patients. PLoS One. 2013. 8(2):e55843. [QxMD MEDLINE Link].

12. Taddio A, Rossetto E, Rosé CD, Brescia AM, Bracaglia C, Cortis E, et al. Prognostic impact of atypical presentation in pediatric systemic lupus erythematosus: results from a multicenter study. J Pediatr. 2010 Jun. 156(6):972-7. [QxMD MEDLINE Link].

13. Ishimori ML, Pressman BD, Wallace DJ, Weisman MH. Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE?. Lupus. 2007. 16(6):436-43. [QxMD MEDLINE Link].

14. Mikdashi J, Krumholz A, Handwerger B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology. 2005 Jun 28. 64(12):2102-7. [QxMD MEDLINE Link].

15. Joseph FG, Lammie GA, Scolding NJ. CNS lupus: a study of 41 patients. Neurology. 2007 Aug 14. 69(7):644-54. [QxMD MEDLINE Link].

16. Keane JR. Eye movement abnormalities in systemic lupus erythematosus. Arch Neurol. 1995 Dec. 52(12):1145-9. [QxMD MEDLINE Link].

17. Hernando Rubio I, Belzunegui Otano J, Máiz Alonso O, Alvarez Rodríguez B. Transverse myelitis and bilateral optic neuritis in a patient with systemic lupus erythematosus. Reumatol Clin. 2012 Sep-Oct. 8(5):298-9. [QxMD MEDLINE Link].

18. Zou X, Zhuang Y, Dong FT, Zhang F, Chen YX. Sequential bilateral central retinal artery occlusion as the primary manifestation of systemic lupus erythematosus. Chin Med J (Engl). 2012 Apr. 125(8):1517-9. [QxMD MEDLINE Link].

19. Lee JH, Sung IY, Park JH, Roh JL. Recurrent laryngeal neuropathy in a systemic lupus erythematosus (SLE) patient. Am J Phys Med Rehabil. 2008 Jan. 87(1):68-70. [QxMD MEDLINE Link].

20. Iannuccelli C, Spinelli FR, Guzzo MP, Priori R, Conti F, Ceccarelli F, et al. Fatigue and widespread pain in systemic lupus erythematosus and Sjögren's syndrome: symptoms of the inflammatory disease or associated fibromyalgia?. Clin Exp Rheumatol. 2012 Nov-Dec. 30(6 Suppl 74):117-21. [QxMD MEDLINE Link].

21. Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol. 2003 May. 30(5):985-92. [QxMD MEDLINE Link].

22. Azarpazhooh MR, Mokhber N, Orouji E, Chambers BR, Hatef MR, Rezaieyazdi Z, et al. Microembolic signals in patients with systemic lupus erythematosus. Can J Neurol Sci. 2010 May. 37(3):371-5. [QxMD MEDLINE Link].

23. Ellis SG, Verity MA. Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955--1977. Semin Arthritis Rheum. 1979 Feb. 8(3):212-21. [QxMD MEDLINE Link].

24. Yuan H, Ni JD, Pan HF, Li LH, Feng JB, Ye DQ. Lack of association of FcgammaRIIIb polymorphisms with systemic lupus erythematosus: a meta-analysis. Rheumatol Int. 2010 Mar 19. [QxMD MEDLINE Link].

25. AlSaleh J, Jassim V, ElSayed M, et al. Clinical and immunological manifestations in 151 SLE patients living in Dubai. Lupus. 2008. 17(1):62-6. [QxMD MEDLINE Link].

26. El-Chennawi FA, Mosaad YM, Habib HM, El-Degheidi T. Comparative study of antinuclear antibody detection by indirect immunofluorescence and enzyme immunoassay in lupus patients. Immunol Invest. 2009. 38(8):839-50. [QxMD MEDLINE Link].

27. Merkel PA, Chang Y, Pierangeli SS, et al. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med. 1996 Dec. 101(6):576-83. [QxMD MEDLINE Link].

28. Choojitarom K, Verasertniyom O, Totemchokchyakarn K, et al. Lupus nephritis and Raynaud's phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. Clin Rheumatol. 2008 Mar. 27(3):345-51. [QxMD MEDLINE Link].

29. Postal M, Lapa AT, Reis F, Rittner L, Appenzeller S. Magnetic resonance imaging in neuropsychiatric systemic lupus erythematosus: current state of the art and novel approaches. Lupus. 2017 Apr. 26 (5):517-521. [QxMD MEDLINE Link].

30. Sarbu N, Toledano P, Calvo A, Roura E, Sarbu MI, Espinosa G, et al. Advanced MRI techniques: biomarkers in neuropsychiatric lupus. Lupus. 2017 Apr. 26 (5):510-516. [QxMD MEDLINE Link].

31. Offenbacher H, Fazekas F, Schmidt R, Freidl W, Flooh E, Payer F. Assessment of MRI criteria for a diagnosis of MS. Neurology. 1993 May. 43(5):905-9. [QxMD MEDLINE Link].

32. Zanardi VA, Magna LA, Costallat LT. Cerebral atrophy related to corticotherapy in systemic lupus erythematosus (SLE). Clin Rheumatol. 2001. 20(4):245-50. [QxMD MEDLINE Link].

33. Castellino G, Padovan M, Bortoluzzi A, et al. Single photon emission computed tomography and magnetic resonance imaging evaluation in SLE patients with and without neuropsychiatric involvement. Rheumatology (Oxford). 2008 Mar. 47(3):319-23. [QxMD MEDLINE Link].

34. Bosma GP, Steens SC, Petropoulos H, Admiraal-Behloul F, van den Haak A, Doornbos J, et al. Multisequence magnetic resonance imaging study of neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2004 Oct. 50 (10):3195-202. [QxMD MEDLINE Link].

35. Magro-Checa C, Ercan E, Wolterbeek R, Emmer B, van der Wee NJ, Middelkoop HA, et al. Changes in White Matter Microstructure Suggest an Inflammatory Origin of Neuropsychiatric Systemic Lupus Erythematosus. Arthritis Rheumatol. 2016 Aug. 68 (8):1945-54. [QxMD MEDLINE Link].

36. Ercan E, Ingo C, Tritanon O, Magro-Checa C, Smith A, Smith S, et al. A multimodal MRI approach to identify and characterize microstructural brain changes in neuropsychiatric systemic lupus erythematosus. Neuroimage Clin. 2015. 8:337-44. [QxMD MEDLINE Link].

37. Hanly JG, Kozora E, Beyea SD, Birnbaum J. Review: Nervous System Disease in Systemic Lupus Erythematosus: Current Status and Future Directions. Arthritis Rheumatol. 2019 Jan. 71 (1):33-42. [QxMD MEDLINE Link].

38. Niu C, Tan X, Liu X, Han K, Niu M, Xu J, et al. Cortical thickness reductions associate with abnormal resting-state functional connectivity in non-neuropsychiatric systemic lupus erythematosus. Brain Imaging Behav. 2018 Jun. 12 (3):674-684. [QxMD MEDLINE Link].

39. Valdés-Ferrer SI, Vega F, Cantú-Brito C, et al. Cerebral changes in SLE with or without antiphospholipid syndrome. a case-control MRI study. J Neuroimaging. 2008 Jan. 18(1):62-5. [QxMD MEDLINE Link].

40. Glanz BI, Laoprasert P, Schur PH, et al. Lateralized EEG findings in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Clin Electroencephalogr. 2001 Jan. 32(1):14-9. [QxMD MEDLINE Link].

41. Coles A. Looks like multiple sclerosis, but the ANA is positive: does my patient have lupus?. Pract Neurol. 2004. 4(4):212-221.

42. Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008 Jan. 65(1):78-83. [QxMD MEDLINE Link].

43. Trevisani VF, Castro AA, Neves Neto JF, Atallah AN. Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev. 2000. CD002265. [QxMD MEDLINE Link].

44. Fernandes Moça Trevisani V, Castro AA, Ferreira Neves Neto J, Atallah AN. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev. 2013 Feb 28. 2:CD002265. [QxMD MEDLINE Link].

45. Jónsdóttir T, Gunnarsson I, Risselada A, et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis. 2008 Mar. 67(3):330-4. [QxMD MEDLINE Link].

46. Ermann J, Bermas BL. The biology behind the new therapies for SLE. Int J Clin Pract. 2007 Dec. 61(12):2113-9. [QxMD MEDLINE Link].

47. Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs. 2010 Mar 26. 70(5):529-40. [QxMD MEDLINE Link].

48. Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017 Feb. 69 (2):376-386. [QxMD MEDLINE Link].

49. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999 Dec. 46(6):878-86. [QxMD MEDLINE Link].

50. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003 Sep 18. 349(12):1133-8. [QxMD MEDLINE Link].

51. Wallace DJ. Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox. Lupus. 2008. 17(2):91-2. [QxMD MEDLINE Link].

Pradeep C Bollu, MD Associate Professor of Neurology, Vice Chair of Quality, Department of Neurology, Prisma Health, University of South Carolina School of Medicine, Columbia

Pradeep C Bollu, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, Boone County Medical Society, Indian Medical Association, Indian Red Cross Society, International Parkinson and Movement Disorder Society, Missouri State Medical Association

Disclosure: Nothing to disclose.

Sireesha Murala, MBBS Postdoctoral Research Associate, Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center

Sireesha Murala, MBBS is a member of the following medical societies: Indian Medical Association, Medical Council of India

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Florian P Thomas, MD, PhD, MA, MS Chair, Neuroscience Institute and Department of Neurology, Director, Hereditary Neuropathy Center, Co-Director, Center for Memory Loss and Brain Health, Co-Director, ALS Center, Hackensack University Medical Center; Associate Dean of Faculty, Founding Chair and Professor, Department of Neurology, Hackensack Meridian School of Medicine

Florian P Thomas, MD, PhD, MA, MS is a member of the following medical societies: Academy of Spinal Cord Injury Professionals, American Academy of Neurology, American Neurological Association, Consortium of Multiple Sclerosis Centers, National Multiple Sclerosis Society, Sigma Xi, The Scientific Research Honor Society

Disclosure: Nothing to disclose.

Niranjan N Singh, MBBS, MD, DM, FAHS, FAANEM Adjunct Associate Professor of Neurology, University of Missouri-Columbia School of Medicine; Medical Director of St Mary's Stroke Program, SSM Neurosciences Institute, SSM Health

Niranjan N Singh, MBBS, MD, DM, FAHS, FAANEM is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American Headache Society

Disclosure: Nothing to disclose.

Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS † Professor Emeritus of Neurology and Psychiatry, Clinical Professor of Medicine, Clinical Professor of Family Medicine, Clinical Professor of Neurosurgery, State University of New York Upstate Medical University; Neuroscience Director, Department of Neurology, Crouse Irving Memorial Hospital

Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS is a member of the following medical societies: American Academy of Neurology, American Academy of Pain Medicine, American College of Forensic Examiners Institute, American College of International Physicians, American College of Physicians, American Heart Association, American Stroke Association, National Association of Managed Care Physicians, Royal College of Physicians, Royal College of Physicians and Surgeons of Canada, Royal College of Surgeons of England, Royal Society of Medicine

Disclosure: Nothing to disclose.

Thomas A Kent, MD Welch Chair in Chemistry Professor, Center for Genomic and Precision Medicine, Institute for Biosciences and Technology, Texas A&M Health Science Center; Adjunct Professor, Stanley H Appel Department of Neurology, Institute for Academic Medicine, Houston Methodist Hospital

Thomas A Kent, MD is a member of the following medical societies: American Academy of Neurology, American Neurological Association, New York Academy of Sciences, Royal Society of Medicine, Sigma Xi, The Scientific Research Honor Society, Stroke Council of the American Heart Association

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article